.jpg)
.png)
Top Stories
JACKSONVILLE, Fla. — The National Lipid Association announced on Friday the recipients of its 2018-19 Junior Faculty Research Awards for Clinical Science and Basic Science. Nathan O. Stitziel, MD, PhD Clinical Science Winner Washington University... more
Adding ezetimibe to statin therapy further lowered cholesterol levels and resulted in fewer cardiovascular events in patients following heart attack More than a decade ago, researchers from Brigham and Women’s Hospital (BWH) demonstrated that a high dose statin, which lowered... more
Oct. 25, 2018 Amgen announced on Wednesday, Oct. 24 it is making evolocumab available at a reduced list price in an effort to improve affordability and access for patients. The announcement represents positive news for patients at risk for cardiovascular events. Key outcomes from Amgen’s... more
Actor John O'Hurley and Dr. Eliot Brinton talk about the seriousness of having high cholesterol and ways to effectively manage the condition. Los Angeles Times Website - June 19, 2012
December 18, 2018 Melissa Goetz Lindsey Sutton Co-Presidents Familial Chylomicronemia Syndrome Foundation 7523 Rowena St San Diego, CA 92119 An Open Letter to Familial Chylomicronemia Syndrome... more
Experiencing side effects such as muscle-related pain or weakness was the top reason why patients stopped taking statins, according to results from a large survey. MedPage Today - June 22, 2012
Pursuant to the advice of the Chapter of the National Lipid Association, the following updates to the Bylaws are proposed to the NLA membership for adoption at the NLA Business Meeting on May 18, 2019. The purpose of the update is to restore the position of the at-large directors on the chapter... more
On Dec. 13, the European Medicines Agency announced that it failed to grant marketing approval for Kynamro (mipomersen sodium) due to concerns about its side effects. Kynamro has been in the Sanofi/Isis Pharmaceuticals pipeline as a therapy intended to treat homozygous FH. The drug is under... more
Following a June 2015 recommendation by the U.S Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee, the FDA has approved alirocumab for patients on maximally tolerated statin therapy with heterozygous familial hypercholesterolemia (HeFH) or with clinical... more
JACKSONVILLE, Fla. (April 12, 2019) — The 2019 National Lipid Association Nominating Committee released its annual report and recommendations on Monday. Chaired by NLA Immediate Past President James A. Underberg, MD, MS, FNLA, the committee compiled a list of recommended candidates to... more